GSA Capital Partners LLP Takes $960,000 Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

GSA Capital Partners LLP bought a new position in Integra LifeSciences Holdings Co. (NASDAQ:IART - Free Report) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 52,850 shares of the life sciences company's stock, valued at approximately $960,000. GSA Capital Partners LLP owned 0.07% of Integra LifeSciences at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. CWM LLC grew its holdings in shares of Integra LifeSciences by 50.8% during the 2nd quarter. CWM LLC now owns 1,262 shares of the life sciences company's stock worth $37,000 after purchasing an additional 425 shares in the last quarter. Blue Trust Inc. raised its position in Integra LifeSciences by 100.5% in the second quarter. Blue Trust Inc. now owns 886 shares of the life sciences company's stock worth $26,000 after purchasing an additional 444 shares in the last quarter. CANADA LIFE ASSURANCE Co lifted its stake in Integra LifeSciences by 1.1% during the first quarter. CANADA LIFE ASSURANCE Co now owns 49,762 shares of the life sciences company's stock worth $1,764,000 after purchasing an additional 551 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Integra LifeSciences by 7.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,454 shares of the life sciences company's stock valued at $421,000 after buying an additional 1,010 shares in the last quarter. Finally, Allspring Global Investments Holdings LLC grew its holdings in shares of Integra LifeSciences by 58.0% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 4,662 shares of the life sciences company's stock worth $136,000 after purchasing an additional 1,711 shares during the last quarter. Institutional investors and hedge funds own 84.78% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on IART shares. Truist Financial cut their target price on shares of Integra LifeSciences from $26.00 to $21.00 and set a "hold" rating for the company in a research note on Monday, October 14th. Citigroup increased their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a "sell" rating in a report on Tuesday, November 5th. Bank of America lowered their target price on Integra LifeSciences from $26.00 to $18.00 and set an "underperform" rating for the company in a research note on Monday, October 7th. JMP Securities reduced their price target on shares of Integra LifeSciences from $40.00 to $35.00 and set a "market outperform" rating on the stock in a research report on Tuesday, July 30th. Finally, BTIG Research upgraded shares of Integra LifeSciences from a "sell" rating to a "neutral" rating in a research report on Monday, October 7th. Three analysts have rated the stock with a sell rating, five have assigned a hold rating and one has assigned a buy rating to the company's stock. According to data from MarketBeat, Integra LifeSciences currently has a consensus rating of "Hold" and a consensus price target of $24.00.

Integra LifeSciences Trading Down 1.7 %

NASDAQ IART traded down $0.39 during trading hours on Friday, hitting $22.88. The company's stock had a trading volume of 763,295 shares, compared to its average volume of 1,100,274. The company has a quick ratio of 0.73, a current ratio of 1.20 and a debt-to-equity ratio of 0.79. Integra LifeSciences Holdings Co. has a twelve month low of $16.81 and a twelve month high of $45.42. The stock has a fifty day moving average of $19.54 and a 200 day moving average of $24.21. The firm has a market capitalization of $1.77 billion, a P/E ratio of -254.22, a PEG ratio of 0.79 and a beta of 1.08.

Integra LifeSciences (NASDAQ:IART - Get Free Report) last issued its earnings results on Monday, November 4th. The life sciences company reported $0.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.39 by $0.02. The firm had revenue of $380.80 million for the quarter, compared to analysts' expectations of $375.81 million. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The company's revenue was down .4% compared to the same quarter last year. During the same quarter last year, the business earned $0.76 earnings per share. Equities research analysts forecast that Integra LifeSciences Holdings Co. will post 2.45 earnings per share for the current fiscal year.

About Integra LifeSciences

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.